Vantage logo

Fate runs out of excuses

The plug is pulled on a deal with J&J, and Fate swings the axe over its staff and NK cell pipeline.

Vantage logo

Treme climbs a new mountain

Astrazeneca’s Himalaya study is a surprising hit in first-line liver cancer, but competition is already present.